BG104119A - A new composition - Google Patents

A new composition

Info

Publication number
BG104119A
BG104119A BG104119A BG10411900A BG104119A BG 104119 A BG104119 A BG 104119A BG 104119 A BG104119 A BG 104119A BG 10411900 A BG10411900 A BG 10411900A BG 104119 A BG104119 A BG 104119A
Authority
BG
Bulgaria
Prior art keywords
new composition
betablocker
reversive
serotonin
pharmaceutical composition
Prior art date
Application number
BG104119A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul CUMMINGS
Ian TULLOCH
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104119A publication Critical patent/BG104119A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG104119A 1997-07-11 2000-02-01 A new composition BG104119A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition
PCT/EP1998/004971 WO1999002142A2 (en) 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker

Publications (1)

Publication Number Publication Date
BG104119A true BG104119A (en) 2000-12-29

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104119A BG104119A (en) 1997-07-11 2000-02-01 A new composition

Country Status (26)

Country Link
EP (1) EP0996466A2 (xx)
JP (1) JP2002508003A (xx)
KR (1) KR20010021644A (xx)
CN (1) CN1262627A (xx)
AP (1) AP2000001728A0 (xx)
AR (1) AR016128A1 (xx)
AU (1) AU9340198A (xx)
BG (1) BG104119A (xx)
BR (1) BR9810996A (xx)
CA (1) CA2295822A1 (xx)
CO (1) CO4950552A1 (xx)
DZ (1) DZ2556A1 (xx)
EA (1) EA200000112A1 (xx)
GB (1) GB9714675D0 (xx)
HU (1) HUP0003074A3 (xx)
ID (1) ID24191A (xx)
IL (1) IL133869A0 (xx)
MA (1) MA24604A1 (xx)
NO (1) NO20000107L (xx)
OA (1) OA11276A (xx)
PE (1) PE99699A1 (xx)
PL (1) PL338017A1 (xx)
SK (1) SK72000A3 (xx)
TR (1) TR200000074T2 (xx)
WO (1) WO1999002142A2 (xx)
ZA (1) ZA986138B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
AU2005283829A1 (en) * 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) * 2006-09-08 2009-03-18 山东益康药业有限公司 复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (de) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
NO20000107D0 (no) 2000-01-10
AU9340198A (en) 1999-02-08
ZA986138B (en) 2000-01-10
ID24191A (id) 2000-07-13
AR016128A1 (es) 2001-06-20
EP0996466A2 (en) 2000-05-03
WO1999002142A3 (en) 1999-04-15
PL338017A1 (en) 2000-09-25
HUP0003074A2 (hu) 2001-01-29
KR20010021644A (ko) 2001-03-15
WO1999002142A2 (en) 1999-01-21
AP2000001728A0 (en) 2000-03-31
NO20000107L (no) 2000-01-10
CN1262627A (zh) 2000-08-09
OA11276A (en) 2003-07-31
BR9810996A (pt) 2000-08-08
TR200000074T2 (tr) 2000-05-22
MA24604A1 (fr) 1999-04-01
IL133869A0 (en) 2001-04-30
PE99699A1 (es) 1999-12-21
CO4950552A1 (es) 2000-09-01
DZ2556A1 (fr) 2003-02-15
CA2295822A1 (en) 1999-01-21
JP2002508003A (ja) 2002-03-12
HUP0003074A3 (en) 2001-12-28
EA200000112A1 (ru) 2000-10-30
GB9714675D0 (en) 1997-09-17
SK72000A3 (en) 2000-12-11

Similar Documents

Publication Publication Date Title
CZ20011427A3 (cs) Farmaceutická kompozice s řízeným uvolňovaním obsahující inhibitor CGMP DPE-5
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
GB2365772A (en) Factor
MXPA98004611A (es) Composicion inhibidora de flama y uso de la misma.
ZA987537B (en) Stanol ester composition and production thereof.
LU91758I9 (xx)
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
YU15299A (sh) Farmaceutski sastavi
IL122447A0 (en) Pharmaceutical composition with anaestheric effect
IL147803A0 (en) 28-epirapalogs
HU9400952D0 (en) Heteroaryl-amines as acetyl-cholinesterase inhibitors
ZA9710593B (en) Antisebum and antioxidant compositions containing gugulipid and fractions thereof.
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
GB9717598D0 (en) Novel composition and use
BG104119A (en) A new composition
BG101401A (en) Cisaspide extended release oral compositions
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
BG100248A (en) Squalene synthetase inhibitors
MD970269A (en) Clavulanates
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
GB9606579D0 (en) Pharmaceutical composition and methods for the manufacture thereof
NZ326769A (en) High-content famciclovir tablets